Open AccessHuman Positive Coactivator 4 Affects the Progression and Prognosis of Pancreatic Ductal Adenocarcinoma via the mTOR/P70s6k Signaling Pathway
Author(s) -
Xingxing Su,
Ying Yang,
Le Ma,
Peng Luo,
Kaicheng Shen,
Hai-Su Dai,
Yan Jiang,
Ling Shuai,
Zhipeng Liu,
Jinshan You,
Ke Min,
Shi Chen,
Zhiyu Chen
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s284219
Subject(s) - pancreatic ductal adenocarcinoma , coactivator , medicine , pi3k/akt/mtor pathway , cancer research , signal transduction , oncology , pancreatic cancer , biology , microbiology and biotechnology , cancer , gene , genetics , transcription factor
Pancreatic cancer is one of the deadliest cancers in the world, and pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of all cases. Human positive coactivator 4 (PC4) is a transcriptional coactivator that has been associated with the development and progression of several tumors. However, no studies investigated the potential role of PC4 in PDAC.